Bringing the fundamentals into focus…
Back to NewAmsterdam Pharma Company N.V.
How NewAmsterdam Pharma Company N.V. stacks up
NAMS · against 552 other Healthcare companies listed in US-listed
Overall
26/ 100
Near the bottom of its peers.
Ranked #477 of 553 · scores higher than 13% of peers
Bars: peers in each 10-point band of the overall score70 peers with an overall score of 20–29, including NAMS · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around NAMS| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 1 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 3 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 609M USD | 91 | 95 | 99 | 99 | 0 / 2 | |
| 477 | 318M USD | 26 | 30 | 29 | 27 | 2 / 2 | |
| 477 | 296M USD | 26 | 8 | 71 | 15 | 2 / 2 | |
| 477 | 8.7B USD | 26 | 8 | 78 | 2 | 2 / 2 | |
| 477 | 1.1B USD | 26 | 8 | 3 | 7 | 0 / 2 | |
| 477 | 2.3B USD | 26 | 8 | 3 | 3 | 0 / 2 | |
| 477 | 107M USD | 26 | 8 | 30 | 23 | 1 / 2 | |
| 477 | 2.0B USD | 26 | 8 | 56 | 14 | 2 / 2 | |
| 485 | 2.3B USD | 25 | 8 | 0 | 4 | 0 / 2 | |
| 485 | 888M USD | 25 | 8 | 3 | 6 | 0 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score